Depression is one of the most common and serious mental health conditions in the world. It affects how people feel, think, and function in daily life.
Many people feel deeply sad, lose interest in things they once enjoyed, and struggle with sleep, energy, and concentration. Although there are many treatments available, such as antidepressant medications and talking therapies, these do not work for everyone.
In fact, more than 30 percent of people with depression do not respond well to current treatments. Even when treatment works, the condition often comes back. Studies suggest that up to 80 percent of people may experience another episode within a year. Because of this, scientists have been searching for new and better ways to treat depression.
One area that has received a lot of attention in recent years is the use of psilocybin. This is a natural compound found in certain types of mushrooms, sometimes called “magic mushrooms.”
Psilocybin affects the brain in ways that can change perception, mood, and thinking. Early research has suggested that, when used carefully in a controlled setting, it may help reduce symptoms of depression.
A large new study has now explored this idea further. The research was led by scientists at the Central Institute of Mental Health in Germany, working together with Charité—Universitätsmedizin Berlin and the MIND Foundation. The study is known as the EPIsoDE trial and its findings were published in the journal JAMA Psychiatry.
The study took place between 2021 and 2024 and included 144 people with treatment-resistant depression. This means their depression had not improved with standard treatments. The researchers wanted to test whether psilocybin, when combined with psychotherapy, could be both effective and safe.
Participants were divided into different groups and received either a high dose of psilocybin, a low dose, or a placebo.
The high dose was 25 milligrams, which was expected to have a strong effect. The low dose, 5 milligrams, was used as a control and was not expected to provide real treatment benefits. A placebo was also included to allow fair comparison.
Importantly, this was not just a drug study. All participants received careful psychological support. Before taking psilocybin, they attended preparation sessions with trained therapists.
During the dosing sessions, they stayed in a calm and comfortable environment with music, and two therapists were present for support. Afterward, they took part in follow-up sessions to help them understand and integrate their experiences into daily life.
The researchers measured changes in depression symptoms at several time points. One key measure was whether symptoms dropped by at least half after treatment. This was checked six weeks after the first session.
The results were mixed but still encouraging. One week after receiving the high dose of psilocybin, more people showed improvement compared to those who received the placebo. However, by six weeks, this difference was no longer strong enough to meet the study’s main goal.
Even so, when looking at other measures, the researchers found clear benefits. After six weeks, people who took the high dose showed greater reductions in depression scores compared to the placebo group. After twelve weeks, when all participants had received the high dose at least once, overall depression symptoms were reduced across the whole group.
The study also looked at safety. Many participants experienced temporary effects during the treatment sessions.
These included strong emotions, vivid mental images, and changes in perception. Some also had physical symptoms such as headaches, increased blood pressure, nausea, and dizziness. Most of these effects were short-lived and went away within a few days.
There were two serious cases, including a strong increase in blood pressure and a longer-lasting change in perception. These cases were carefully managed by the medical team. Overall, the researchers considered the treatment to have a good safety profile when delivered with proper support.
The study also explored how psilocybin might work. Many participants reported what researchers call “emotional breakthroughs.” These are moments of deep emotional insight and openness during the treatment.
The study found that people who had stronger emotional breakthroughs tended to show greater improvement in depression symptoms. This suggests that these experiences may play an important role in how the treatment works.
There are several strengths in this study. It was carefully designed, included a relatively large group of participants, and combined medical treatment with structured psychotherapy. It also followed participants over time to assess longer-term effects.
However, there are also important limitations. The main goal of the study was not fully achieved, which means the results are not yet strong enough to confirm psilocybin as a standard treatment.
The sample size, while larger than many earlier studies, is still limited. In addition, the treatment requires trained therapists and controlled environments, which may not be easy to provide in everyday healthcare settings.
In conclusion, this study adds to growing evidence that psilocybin, when combined with psychotherapy, may help reduce symptoms of depression, especially in people who have not responded to other treatments.
However, it is not a simple or quick solution. The results show both promise and caution. More research is needed to better understand how the treatment works, who benefits most, and how it can be used safely in the future.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more health information, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
Copyright © 2026 Knowridge Science Report. All rights reserved.
